Literature DB >> 1378619

Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens.

J Karttunen1, S Sanderson, N Shastri.   

Abstract

The alpha/beta T-cell receptor a complex ligand formed by the association of antigenic peptides with molecules of the major histocompatibility complex (MHC). The inherent limitations of the conventional T-cell activation assays used to detect these peptide/MHC ligands have, until now, hampered the development of expression cloning systems for T-cell antigens. To overcome these limitations, we have recently introduced a method for detecting ligand-induced activation of individual T cells. This assay, which makes use of a lacZ reporter construct, differs from conventional ligand-induced activation assays in that it allows the detection of single, activated T cells in large pools of resting cells. We applied the lacZ assay to the problem of screening expression libraries, which requires the ability to detect ligand-bearing antigen-presenting cells when they are present at very low frequency. We show here that ligand-expressing antigen-presenting cells can be detected at frequencies of 1:10(3)-10(4), a level of sensitivity compatible with the screening of cDNA libraries. Furthermore, by using as antigen-presenting cells COS-7 cells stably transfected with the murine Kb class I MHC molecule, we demonstrate that transiently expressed ovalbumin is efficiently processed and presented to an ovalbumin/Kb-specific T-cell hybridoma. lacZ expression is induced in a detectable number of cocultured T cells, even when the ovalbumin cDNA consists of only 1:10(4) of the total DNA used to transfect the COS cells. These results suggest that unknown T-cell antigens may be identified by screening cDNA libraries in MHC-expressing COS cells using lacZ-inducible T cells as indicators of peptide antigen expression.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378619      PMCID: PMC402130          DOI: 10.1073/pnas.89.13.6020

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis.

Authors:  E R Christinck; M A Luscher; B H Barber; D B Williams
Journal:  Nature       Date:  1991-07-04       Impact factor: 49.962

2.  Requirement for association of p56lck with CD4 in antigen-specific signal transduction in T cells.

Authors:  N Glaichenhaus; N Shastri; D R Littman; J M Turner
Journal:  Cell       Date:  1991-02-08       Impact factor: 41.582

Review 3.  Genes coding for T-cell-defined tum transplantation antigens: point mutations, antigenic peptides, and subgenic expression.

Authors:  T Boon; A Van Pel; E De Plaen; P Chomez; C Lurquin; J P Szikora; C Sibille; B Mariamé; B Van den Eynde; B Lethé
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1989

4.  IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement.

Authors:  M Sarmiento; A L Glasebrook; F W Fitch
Journal:  J Immunol       Date:  1980-12       Impact factor: 5.422

5.  Single cell assay of a transcription factor reveals a threshold in transcription activated by signals emanating from the T-cell antigen receptor.

Authors:  S Fiering; J P Northrop; G P Nolan; P S Mattila; G R Crabtree; L A Herzenberg
Journal:  Genes Dev       Date:  1990-10       Impact factor: 11.361

6.  Measurement of ligand-induced activation in single viable T cells using the lacZ reporter gene.

Authors:  J Karttunen; N Shastri
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

7.  Monoclonal antibodies to mouse MHC antigens. III. Hybridoma antibodies reacting to antigens of the H-2b haplotype reveal genetic control of isotype expression.

Authors:  K Ozato; D H Sachs
Journal:  J Immunol       Date:  1981-01       Impact factor: 5.422

8.  Use of a recombinant retrovirus to study post-implantation cell lineage in mouse embryos.

Authors:  J R Sanes; J L Rubenstein; J F Nicolas
Journal:  EMBO J       Date:  1986-12-01       Impact factor: 11.598

9.  Ia molecule-associated selectivity in T cell recognition of a 23-amino-acid peptide of lysozyme.

Authors:  N Shastri; G Gammon; A Miller; E E Sercarz
Journal:  J Exp Med       Date:  1986-09-01       Impact factor: 14.307

10.  Reactivity of V beta 17a+ CD8+ T cell hybrids. Analysis using a new CD8+ T cell fusion partner.

Authors:  H G Burgert; J White; H U Weltzien; P Marrack; J W Kappler
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

View more
  149 in total

1.  Delivery of CD8(+) T-cell epitopes into major histocompatibility complex class I antigen presentation pathway by Bordetella pertussis adenylate cyclase: delineation of cell invasive structures and permissive insertion sites.

Authors:  R Osicka; A Osicková; T Basar; P Guermonprez; M Rojas; C Leclerc; P Sebo
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

2.  Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity.

Authors:  C Fayolle; A Osickova; R Osicka; T Henry; M J Rojas; M F Saron; P Sebo; C Leclerc
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  A single nucleotide polymorphism in the Emp3 gene defines the H4 minor histocompatibility antigen.

Authors:  Brianna Luedtke; Laura M Pooler; Eun Young Choi; Angela M Tranchita; Corbett J A Reinbold; Aaron C Brown; Daniel J Shaffer; Derry C Roopenian; Subramaniam Malarkannan
Journal:  Immunogenetics       Date:  2003-07-04       Impact factor: 2.846

4.  Distinct migrating and nonmigrating dendritic cell populations are involved in MHC class I-restricted antigen presentation after lung infection with virus.

Authors:  Gabrielle T Belz; Christopher M Smith; Lauren Kleinert; Patrick Reading; Andrew Brooks; Ken Shortman; Francis R Carbone; William R Heath
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-26       Impact factor: 11.205

5.  The pathway of cross-presentation is influenced by the particle size of phagocytosed antigen.

Authors:  Alexandra Mant; Fay Chinnery; Tim Elliott; Anthony P Williams
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

6.  Complexes of streptavidin-fused antigens with biotinylated antibodies targeting receptors on dendritic cell surface: a novel tool for induction of specific T-cell immune responses.

Authors:  Ondrej Stanek; Irena Linhartova; Laleh Majlessi; Claude Leclerc; Peter Sebo
Journal:  Mol Biotechnol       Date:  2012-07       Impact factor: 2.695

7.  The Toxoplasma gondii peptide AS15 elicits CD4 T cells that can control parasite burden.

Authors:  Harshita Satija Grover; Nicolas Blanchard; Federico Gonzalez; Shiao Chan; Ellen A Robey; Nilabh Shastri
Journal:  Infect Immun       Date:  2012-07-09       Impact factor: 3.441

8.  Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.

Authors:  Ling Zhang; Sid P Kerkar; Zhiya Yu; Zhili Zheng; Shicheng Yang; Nicholas P Restifo; Steven A Rosenberg; Richard A Morgan
Journal:  Mol Ther       Date:  2011-02-01       Impact factor: 11.454

9.  Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue.

Authors:  A Porgador; H F Staats; Y Itoh; B L Kelsall
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

10.  A safe bacterial microsyringe for in vivo antigen delivery and immunotherapy.

Authors:  Audrey Le Gouëllec; Xavier Chauchet; David Laurin; Caroline Aspord; Julien Verove; Yan Wang; Charlotte Genestet; Candice Trocme; Mitra Ahmadi; Sandrine Martin; Alexis Broisat; François Cretin; Catherine Ghezzi; Benoit Polack; Joël Plumas; Bertrand Toussaint
Journal:  Mol Ther       Date:  2013-03-26       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.